N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: Effect on cellular ligand trafficking in vitro and tumor accumulation in vivo

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2778-2789

  Schottelius, Margret ^a   Reubi, Jean Claude ^b   Eltschinger, Veronique ^b   Schwaiger, Markus ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIM 23027; CARBOHYDRATE DERIVATIVE; GALACTOSE S OCTREOTATE[3 TYROSINE] I 123; GLUCOSE; GLUCOSE OCTREOTATE[3 TYROSINE] I 123; GLUCOSE OCTREOTIDE[3 TYROSINE] I 123; GLUCOSE S OCTREOTATE[3 TYROSINE] I 123; MALTOSE OCTREOTATE[3 TYROSINE] I 123; MALTOSE OCTREOTIDE[3 TYROSINE] I 123; MALTOTRIOSE OCTREOTATE[3 TYROSINE] I 123; MALTOTRIOSE OCTREOTIDE[3 TYROSINE] I 123; OCTREOTATE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] I 125; SOMATOSTATIN 28; SOMATOSTATIN 28 [8 LEUCINE 22 DEXTRO TRYPTOPHAN 25 TRYPTOPHAN] I 125; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; THREONINE; TRACER; UNCLASSIFIED DRUG;

AMADORI REARRANGEMENT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONJUGATION; DERIVATIZATION; DRUG RECEPTOR BINDING; DRUG TUMOR LEVEL; FEMALE; GENE EXPRESSION; GLYCOSYLATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGAND BINDING; MOUSE; NONHUMAN; RADIOIODINATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CRICETINAE; CRICETULUS; FEMALE; GLUCOSE; GLYCOSYLATION; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LIGANDS; MALTOSE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRISACCHARIDES;

EID: 15244346845     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040794i     Document Type: Article

References (54)

1. Reubi, J. C.; Krenning, E.; Lamberts, S. W.; Kvols, L. Somatostatin receptors in malignant tissues. J. Steroid Biochem. Mol. Biol. 1990, 37 (6), 1073-1077.
2. Reubi, J. C.; Laderach, U.; Waser, B.; Gebbers, J. O.; Robberecht, P.; Laissue, J. A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000, 60 (11), 3105-3112.
3. Reubi, J. C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N.Y. Acad. Sci. 2000, 921, 1-25.
4. Reubi, J. C.; Gugger, M.; Waser, B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2002, 29 (7), 855-862.
5. Reubi, J. C.; Waser, B.; Schaer, J. C.; Laissue, J. A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int. J. Cancer 1999, 82 (2), 213-218.
6. Reubi, J. C.; Zimmermann, A.; Jonas, S.; Waser, B.; Neuhaus, P.; Laderach, U.; Wiedenmann, B. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999, 45, 766-774.
7. 125I-[D-TYR6,beta-ALA11,PHE13,NLE14]bombesin(6-14). Clin. Cancer Res. 2002, 8 (4), 1139-1146.
8. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997, 57 (7), 1377-1386.
9. Cassoni, P.; Sapino, A.; Stella, A.; Fortunati, N.; Bussolati, G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int. J. Cancer 1998, 77 (5), 695-700.
10. Bussolati, G.; Cassoni, P.; Ghisolfi, G.; Negro, F.; Sapino, A. Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast. Am. J. Pathol. 1996, 148 (6), 1895-1903.
11. North, W. G. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp. Physiol. 2000, 85, 27S-40S.
12. Reubi, J. C. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med. 1997, 41, 63-70.
13. Bruns, C.; Stolz, B.; Albert, R.; Marbach, P.; Pless, J. OctreoScan 111 for imaging of a somatostatin receptor-positive islet cell tumor in rat. Horm. Metab. Res., Suppl. 1993, 27, 5-11
14. Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.; Breeman, W. A.; Kooij, P. P.; Oei, H. Y.; van Hagen, M.; Postema, P. T.; de Jong, M.; Reubi, J. C.; Visser, T. J.; Reijs, A. E. M.; Hofland, L. J.; Koper, J. W.; Lamberts, S. W. J. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20 (8), 716-731.
15. Otte, A.; Jermann, E.; Béhé, M.; Goetze, M.; Bucher, H. C.; Roser, H. W.; Heppeler, A.; Mueller-Brand, J.; Mäcke, H. R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med. 1997, 24 (7), 792-795.
16. Otte, A.; Herrmann, R.; Heppeler, A.; Béhé, M.; Jermann, E.; Powell, P.; Maecke, H. R.; Muller, J. Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med. 1999, 26 (11), 1439-1447.
17. Waldherr, C.; Pless, M.; Maecke, H. R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E. U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (9O)Y-DOTATOC. J. Nucl. Med. 2002, 43, 610-616.
18. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer, W.; Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 1994, 331 (17), 1116-1121
19. 99mTc. J. Nucl. Med. 2002, 43, 374-383.
20. Behr, T. M.; Jenner, N.; Béhé, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J. Nucl. Med. 1999, 40 (6), 1029-1044.
21. 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 1999, 40 (12), 2081-2087.
22. 111In-DTPA-Pro1-Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer 1999, 83 (5), 657-663.
23. 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl. Med. Biol. 2002, 29, 553-560.
24. 2 receptors and associated agonists. Biochem. J. 1998, 336, 291-298.
25. Csaba, Z.; Bernard, V.; Helboe, L.; Bluet-Pajot, M. T.; Bloch, B.; Epelbaum, J.; Dournaud, P. In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway. Mol. Cell. Neurosci. 2001, 17, 646-661.
26. Hukovic, N.; Panetta, R.; Kumar, U.; Patel, Y. C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology 1998, 137, 4046-4049.
27. Froidevaux, S.; Hintermann, E.; Török, M.; Mäcke, H. R.; Beglinger, C.; Eberle, A. N. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res. 1999, 59, 3652-3657.
28. 125I-Tyr3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 1995, 136, 3698-3706.
29. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998, 58, 437-441.
30. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J. Med. Chem. 1999, 42, 1341-1347.
31. 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats. Nucl. Med. Biol. 2001, 28, 327-334.
32. 0]octreotide in patients. Eur. J. Nucl. Med. 2001, 28, 1319-1325.
33. De Jong, M.; Valkema, R.; Jamar, F.; Kvols, L. K.; Kwekkeboom, D. J.; Breeman, W. A.; Bakker, W. H.; Smith, C.; Pauwels, S.; Krenning, E. P. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med. 2002, 32, 133-140.
34. Valkema, R.; de Jong, M.; Bakker, W. H.; Breeman, W. A.; Kooij, P. P.; Lugtenburg, P. J.; de Jong, F. H.; Christiansen, A.; Kam, B. L.; de Herder, W. W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E. P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. 2002, 32, 110-122.
35. 1]-octreotide in patients with neuroendocrine tumors. J. Nucl. Med. 2000, 41, 1514-1518.
36. Froidevaux, S.; Eberle, A. N.; Christe, M.; Sumanovski, L.; Heppeler, A.; Schmitt, J. S.; Eisenwiener, K.; Beglinger, C.; Mäcke, H. R. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int. J. Cancer 2002, 98, 930-937.
37. Duncan J. R.; Stephenson, M. T.; Wu, H. P.; Anderson, C. J. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 1997, 57 (4), 659-671.
38. Bass, L. A.; Lanahan, M. V.; Duncan, J. R.; Erion, J. L.; Srinivasan, A.; Schmidt, M. A.; Anderson, C. J. Identification of the soluble in vivo metabolites of indium-111-diethy-lenetriaminepentaacetic acid-D-Phel-octreotide. Bioconjugate Chem. 1998, 9 (2), 192-200.
39. Schottelius, M.; Wester, H. J.; Reubi, J. C.; Senekowitsch-Schmidtke, R.; Schwaiger, M. Improvement of pharmacokinetics of radioiodinated Tyr3-octreotide by conjugation with carbohydrates. Bioconjugate Chem. 2002, 13 (5), 1021-1030.
40. Wester, H. J.; Schottelius, M.; Scheidhauer, K.; Reubi, J. C.; Wolf, I.; Schwaiger, M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med. Mol. Imaging 2002, 29 (1), 28-38.
41. Vaidyanathan, G.; Friedman, H. S.; Schottelius, M.; Wester, H. J.; Zalutsky, M. R. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin. Cancer Res. 2003, 9 (5), 1868-1876.
42. 3-octreotide indicate a high potential of glycated, radiometalated octreotide derivatives for diagnosis and therapy. Nucl. Med. Commun. 2000, 21, 579 (abstract).
43. 3-labeled carbohydrated SSTR-ligands: synthesis, internalisation kinetics and biodistribution on a rat pancreatic tumor model J. Nucl. Med. 2001, 42 (Suppl.), 115P (abstract).
44. 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. 2003, 30, 117-122.
45. 18F-labelled tracer suitable for routine clinical imaging of sst-receptor expressing tumors using positron emission tomography. Clin. Cancer Res. 2004, 10, 3593-3606.
46. 13C NMR-Untersuchungen an Mutarotationsgemischen C-6- und C-4- sowie C-6-modifizierter Amadoriverbindungen. Liebigs Ann. Chem. 1978, 2099-2104.
47. Wester, H. J.; Schottelius, M.; Schwaiger, M. Glycation of sst-receptor-agonists: improvement of dynamic ligand trafficking of radiolabelled somatostatin analogs. J. Labelled Compd. Radiopharm. 2001, 44 (Suppl. 1), S93.
48. Reubi, J. C.; Schaer, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Maecke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
49. 3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radioguided surgery. Proc. Assoc. Am. Physicians 1999, 111, 63-69.
50. Albert, R.; Marbach, P.; Bauer, W.; Briner, U.; Flicker, G.; Bruns, C.; Pless, J. SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci. 1993, 53, 517-525.
51. Law, P. Y.; Maestri-El Kouhen, O.; Solberg, J.; Wang, W.; Erickson, L. J.; Loh, H. H. Deltorphin II-induced rapid desensitization of δ-opioid receptor requires both phosphorylation and internalization of the receptor. J. Biol. Chem. 2000, 275, 32057-32065.
52. Marie, N.; Lecoq, I.; Jauzac, P.; Allouche, S. Differential sorting of human δ-opioid receptors after internalization by peptide and alkaloid agonists. J. Biol. Chem. 2003, 278, 22795-22804.
53. Kokotos, G. A convenient one-pot conversion of N-protected amino acids and peptides into alcohols. Synthesis 1990, 299-301.
54. Elofsson, M.; Walse, B.; Kihlberg, J. Building blocks for glycopeptide synthesis: Glycosylation of 3-mercaptopropionic acid and Fmoc-amino acids with unprotected carboxyl groups. Tetrahedron Lett. 1991, 32, 7613-7616.